Telmisartan

ARBprescriptionoral · inferred

Longest-half-life angiotensin II receptor blocker (~24 h), providing smooth 24-hour blood pressure control and trough-to-peak ratios exceeding 80%. Indicated for hypertension and cardiovascular risk reduction. Unique PPAR-gamma partial agonism may contribute to metabolic effects. Typical dose 20-80 mg once daily.

Projected serum levels — 40 mg, once daily

Telmisartan

Maintenance only With loading dose

Maintenance schedule: 40 mg once daily (oral).

Loading schedule: 78.1 mg on day 1, then 40 mg once daily — reaching therapeutic levels sooner.

Modeled steady state after ~2 days: peak ≈ 37.9 mg, trough ≈ 19.5 mg body load. Population-based estimate over 15 days for a 40 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category: ARB
Route modeled: Oral
Model confidence: inferred
Half-life: 24 h
Common dose: 40 mg
Suggested maximum: 80 mg/day
Reference dose range: 20–80 mg (single dose)
Suggested cadence: once daily
Validated against: 80 mg oral — Cmax 1 mg/L at 1 h

Documented interactions

danger
Levothyroxine (Synthroid) + Telmisartan Protein binding
Telmisartan may displace Levothyroxine (Synthroid) from plasma protein binding sites, transiently raising free drug concentration. This drug has a narrow therapeutic index; free concentration changes…
warning
Apigenin + Telmisartan Protein binding
Apigenin may displace Telmisartan from plasma protein binding sites, transiently raising free drug concentration.
warning
Aripiprazole (Abilify) + Telmisartan Protein binding
Aripiprazole (Abilify) may displace Telmisartan from plasma protein binding sites, transiently raising free drug concentration.
warning
Armour Thyroid (Desiccated Thyroid Extract) + Telmisartan Protein binding
Telmisartan may displace Armour Thyroid (Desiccated Thyroid Extract) from plasma protein binding sites, transiently raising free drug concentration.
warning
Astaxanthin + Telmisartan Protein binding
Astaxanthin may displace Telmisartan from plasma protein binding sites, transiently raising free drug concentration.
warning
Atomoxetine (Strattera) + Telmisartan Protein binding
Atomoxetine (Strattera) may displace Telmisartan from plasma protein binding sites, transiently raising free drug concentration.

Serum checks 242 modeled interaction pairings for telmisartan across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

Telmisartan, ramipril, or both in patients at high risk for vascular events ONTARGET Investigators (Yusuf S et al.) · New England Journal of Medicine, 2008 DOI
ONTARGET RCT of 25620 high-risk patients showed telmisartan was non-inferior to ramipril for the composite of CV death, MI, stroke, or HF hospitalization, with fewer cough and angioedema events.
Telmisartan to prevent recurrent stroke and cardiovascular events Yusuf S et al. (PRoFESS Study Group) · New England Journal of Medicine, 2008 DOI
PRoFESS trial in 20332 recent ischemic stroke patients found telmisartan did not significantly reduce recurrent stroke vs placebo over 2.5 years, though secondary CV endpoints trended favorably.
Clinical pharmacokinetics of telmisartan Stangier J, Su CA, Roth W · Clinical Pharmacokinetics, 2000 DOI
PK review establishing telmisartan's 42-58% bioavailability, 24-hour terminal half-life, and near-complete biliary elimination as unchanged drug.

3 published studies referenced in the app, each with a plain-language summary.